中华医学会生殖医学分会年度报告:2017年辅助生殖技术数据分析

目的汇报中国辅助生殖技术(ART)2017年年度情况,以期为中国的ART技术发展、标准化建设和质量控制提供依据。方法运用“中华医学会生殖医学分会(CSRM)数据上报系统”,汇总中国内地216家生殖中心上报的2017年ART数据,对ART技术的应用情况进行横断面调查。结果2017年CSRM数据上报系统共报告AID/AIH治疗周期数94131、取卵周期数266579、鲜胚移植周期数117253、冻融胚胎移植(FET)周期数198918。患者年龄主要集中在<35岁组,占比70.19%。新鲜取卵周期妊娠率52.63%、活产率43.03%;FET周期妊娠率50.80%、活产率40.19%。ART并发症中,中重度OHSS发生率为1.59%,术后出血发生率为0.02%,术后盆腔感染发生率为0.01%,其他并发症发生率为0.03%。结论从“CSRM数据上报系统”所获得2017年ART年度情况显示,中国大陆地区的ART周期数多,具有良好的妊娠结局和极低的合并症。

Chinese Society of Reproductive Medicine Annual Report:data analysis of ART in 2017

Objective:To report the Chinese ART data in 2017 to provide a basis for the use and improvement of various technologies and quality control.Methods:The data of ART of 216 Reproductive Centers in the mainland of China in 2017 were collected by CSRM ART Data Reporting System.A cross-sectional survey of the use of ART was performed.Results:In 2017,the CSRM data reporting system reported 94131 AID/AIH cycles,266579 fresh oocyte retrieval cycles,117253 fresh embryo transfer cycles,198918 frozen-thawed embryo transfer(FET)cycles.The patient's age was mainly concentrated in the group<35 years old,accounting for 70.19%.The pregnancy rate and live birth rate of fresh oocyte retrieval cycles were 52.63%and 43.03%respectively.The pregnancy rate and live birth rate of FET cycles were 50.80%and 40.19%respectively.Among ART complications,the incidence of moderate to severe OHSS was 1.59%,postoperative bleeding 0.02%,postoperative pelvic infection 0.01%,and the other complications 0.03%.Conclusions:This study used“CSRM Data Reporting System”data to describe and analyze the status of ART,and observed that most cycles with good outcomes and low incidence rate of complications in China's Mainland.